Printer Friendly

Nordea cuts stance on AstraZeneca.

NORDIC BUSINESS REPORT-31 May 2010-Nordea cuts stance on AstraZeneca(C)1994-2010 M2 COMMUNICATIONS http://www.m2.com

31 May 2010 - Nordea downgraded on Monday its rating on Anglo-Swedish pharma major AstraZeneca (STO: AZN) (NYSE: AZN) to "sell" from "hold", cutting the share price target to USD41 from USD49.

Last Friday, the American depository receipt (ADR) in AstraZeneca closed at USD42.25 on the New York Stock Exchange. In Stockholm, the company's shares had edged down 0.70% to SEK326.70 by 11:42 CET on Monday.

(EUR1 = USD1.2; EUR1 = SEK9.6)

((Comments on this story may be sent to nbr.feedback@nordicbusinessreport.com))

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Date:May 31, 2010
Words:104
Previous Article:CEO to leave Neurosearch for ALK-Abello.
Next Article:Norwegian AGR Group net loss narrows to NOK14.8m in Q1 2010.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters